This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Parent, R. A. Articles by Long, J. E. Search for Related Content PubMed Articles by Parent, R. A. Articles by Long, J. E. Social Bookmarking                         What's this?

Oncogenicity Study of Acrolein in Mice

Consultox, Ltd., P. O. Box 14082, Baton Rouge, Louisiana 70898.

Halina E. Caravello

Baker Performance Chemicals, Inc., 3920 Essex Lane, Houston, Texas 77027.

James E. Long

Biosearch, Inc., P. O. Box 8598, Philadelphia, Pennsylvania 19101.

Five hundred seventy CD-1 mice were divided equally by gender and assigned to three groups of 70 per gender and one group of 75 per gender. The first three groups were dosed via oral intubation at 0, 0.5, and 2.0 mg/kg/day while the larger groups were dosed at 4.5 mg/kg/day. Observations were made twice daily and blood smears taken at 12 and 18 months. All animals were sacrificed at 18 months; organs were weighed and examined grossly and microscopically. Treated animals showed decreased body weight gain and male mice demonstrated increased mortality, particularly at the high-dose level. Gross and microscopic lesions were not obviously dose dependent. In this study, acrolein was not shown to have oncogenic properties.

International Journal of Toxicology, Vol. 10, No. 6, 647-659 (1991)
DOI: 10.3109/10915819109078657


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?